FDA gives Glenmark's generic Evoclin tentative approval
Glenmark Pharmaceuticals has received tentative approval from the Food and Drug Administration for clindamycin phosphate foam, 1%.
The product is a generic of Mylan’s Evoclin foam, 1%.
It is used to treat severe acne in adults and children who are at least 12 years old.
Evoclin foam, 1%, had a market value of roughly $17 million for the year ended April 2019, according to IQVIA.
The product is a generic of Mylan’s Evoclin foam, 1%.
It is used to treat severe acne in adults and children who are at least 12 years old.
Evoclin foam, 1%, had a market value of roughly $17 million for the year ended April 2019, according to IQVIA.